Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Recent headlines about semaglutide shortages have sparked patient concern, but the medication remains accessible through licensed compounding pharmacies across all 50 states. While brand-name Ozempic and Wegovy have faced intermittent supply constraints, compounded semaglutide offers a consistent, affordable alternative for weight management. PlexusDx connects patients with FDA-regulated compounding pharmacies and personalized peptide therapy based on genetic pathways.

Why People Think Semaglutide Is Being Discontinued

Confusion about semaglutide availability stems from real but temporary supply issues with brand-name formulations. In 2023 and early 2024, Novo Nordisk reported manufacturing constraints that limited Ozempic and Wegovy stock at retail pharmacies. Media coverage of these shortages created the false impression that semaglutide itself was being phased out or removed from the market entirely. However, the FDA has not pulled semaglutide from the market, and no regulatory ban exists.

Compounded semaglutide operates under a separate supply chain through licensed 503A compounding pharmacies, which manufacture medications on-demand rather than relying on centralized brand-name production. This decentralized model has helped compounded versions maintain steadier availability even during brand-name shortages. PlexusDx partners exclusively with licensed 503A compounding pharmacies to ensure medication quality, safety, and consistent access for patients pursuing weight loss therapy.

Understanding Compounded Semaglutide vs. Brand-Name Versions

Compounded semaglutide contains the same active pharmaceutical ingredient as Ozempic and Wegovy but is created by licensed pharmacies under FDA oversight through the 503A pathway. These pharmacies follow stringent quality standards, including sterility testing, potency verification, and ingredient authentication. The main differences from brand products are cost, customization of dose strength, and production flexibility—compounded versions can be manufactured quickly in response to patient demand without the supply bottlenecks that affect mass-produced brand medications.

Brand-name semaglutide (Ozempic for diabetes, Wegovy for weight loss) is manufactured by Novo Nordisk in centralized facilities. While brand products have an extensive clinical trial history and FDA approval as finished dosage forms, compounded versions offer comparable therapeutic outcomes at a fraction of the cost. PlexusDx's compounded semaglutide injection starts at $149 per month, eliminating insurance dependence and membership fees while maintaining the same mechanism—GLP-1 receptor activation for appetite reduction and improved metabolic control.

Current Semaglutide Availability and How to Access It Safely

Semaglutide remains available in both brand-name and compounded forms throughout the United States. Brand-name supply has stabilized significantly in 2024 as Novo Nordisk increased manufacturing capacity, though occasional regional shortages may still occur. Compounded semaglutide is available immediately without insurance requirements through PlexusDx, serving all 50 states with medications sourced from licensed 503A compounding pharmacies. Patient-initiated telehealth consultations connect you with clinicians who evaluate candidacy and prescribe personalized dosing protocols.

Safe access requires working with licensed pharmacies and qualified prescribers who conduct medical history reviews, monitor side effects, and adjust treatment plans. PlexusDx requires an initial consultation to assess weight loss goals, metabolic factors, and medication history before prescribing. The Precision Peptide Genetic Test (added after the first month of treatment for $99) identifies individual variations in GLP-1 receptor sensitivity, GIPR activation, and appetite-regulation pathways—enabling truly personalized therapy that maximizes results and minimizes adverse effects. Compounded medications are HSA and FSA eligible, providing additional cost flexibility.

Exploring Alternatives: Tirzepatide and Dual-Compound GLP-1 Options

If semaglutide supply concerns persist or if response is suboptimal, tirzepatide (Zepbound, Mounjaro) represents a proven alternative with a complementary mechanism. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors, producing greater weight loss than semaglutide alone in head-to-head trials. Clinical data from the SURMOUNT trials demonstrated approximately 20% body weight reduction over 68 weeks with tirzepatide versus 15% with semaglutide. PlexusDx offers compounded tirzepatide injection starting at $249 per month, with the same transparent, dose-independent pricing model.

For patients seeking maximum efficacy, PlexusDx's GLP-Squared Injection combines semaglutide and tirzepatide in a dual-compound formulation starting at $249 per month. This synergistic approach targets multiple peptide pathways simultaneously, potentially increasing satiety signaling and metabolic rate more effectively than monotherapy. The Precision Peptide Genetic Test reveals individual variations in GIPR rs1800437, GLP1R rs6923761, MC4R rs17782313, and FTO rs9939609—markers that predict responsiveness to dual-agonist therapy. For those preferring oral formulations, semaglutide oral (starts at $249/mo), tirzepatide oral (starts at $279/mo), and GLP-Squared Oral (starts at $369/mo) eliminate injection discomfort without sacrificing clinical outcomes.

The Role of Genetic Testing in Personalized GLP-1 Therapy

PlexusDx's Precision Peptide Genetic Test goes beyond traditional pharmacogenomics to map 14 metabolic pathways, 49 peptides, and 150+ genetic insights that determine individual responsiveness to GLP-1 medications. Unlike pharmacogenomic tests focused on drug metabolism, the Precision Peptide test identifies functional variations in appetite regulation, satiety signaling, and energy expenditure—directly relevant to weight loss outcomes. Variants in the GLP1R gene (rs6923761) influence receptor sensitivity to semaglutide and tirzepatide, while GIPR rs1800437 predicts response to dual-agonist therapy. FTO rs9939609 correlates with baseline obesity risk, and MC4R rs17782313 affects melanocortin pathway activation.

This personalized approach eliminates guesswork from medication selection and dosing. Patients with genetic variants indicating strong GLP1R sensitivity may achieve target weight loss with lower semaglutide doses, minimizing nausea and gastrointestinal side effects. Those with GIPR variants favoring dual-agonist response may be better candidates for tirzepatide or GLP-Squared combination therapy. The genetic test adds only $99 after the first treatment month, providing years of data-driven confidence in medication choice—ensuring your dose may need to go up, but your price won't.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide actually being pulled from the market?

No. The FDA has not discontinued semaglutide, and no regulatory ban exists. Confusion arose from temporary supply shortages of brand-name Ozempic and Wegovy in 2023–2024, but compounded semaglutide remains consistently available through licensed 503A compounding pharmacies. PlexusDx serves all 50 states with reliable access starting at $149 per month.

How is compounded semaglutide different from brand-name Ozempic or Wegovy?

Compounded semaglutide contains identical active ingredient but is created by licensed pharmacies on-demand rather than mass-produced. Both are equivalent clinically, but compounded versions cost significantly less (starting at $149/mo versus $900+/mo brand), require no insurance, and avoid supply chain delays. All PlexusDx medications come from FDA-regulated 503A compounding pharmacies.

What is the PlexusDx Precision Peptide Genetic Test, and why does it matter?

The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights to predict individual GLP-1 medication response—not just drug metabolism. Variants in GLP1R, GIPR, FTO, and MC4R genes determine whether you'll respond best to semaglutide, tirzepatide, or dual-compound therapy. Adding the test after your first month for $99 optimizes medication choice and dosing for maximum results.

How much does compounded semaglutide cost, and is it covered by insurance?

PlexusDx compounded semaglutide injection starts at $149 per month with transparent, dose-independent pricing—your price won't increase as your dose adjusts. No insurance is required, and the medication is HSA and FSA eligible. All 50 states are served with no membership fees.

Is compounded semaglutide safe and FDA-approved?

Compounded semaglutide is safe and manufactured by licensed 503A compounding pharmacies under FDA oversight. While compounded medications are not FDA-approved as finished products, they meet rigorous quality, sterility, and potency standards. The active ingredient (semaglutide) is FDA-approved, and compounding follows strict regulatory pathways. PlexusDx partners only with verified licensed pharmacies to ensure safety.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves